Adlai Nortye Group Ltd. - American Depositary Shares (NQ:ANL)

Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab

October 15, 2026

Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations

Performance

52-Week Range 44.3% below 52-week high

9.605

0.8852W Low 17.2552W High

1 Week 13.9% below 1-week high

9.361W Low 11.151W High

Adlai Nortye Group Ltd. - American Depositary Shares (ANL) traded between $0.88 and $17.25 over the past 52 weeks and last traded at $9.61, 44.3% below its 52-week high. Over the past week it ranged between $9.36 and $11.15.

Past 12 Months

-9.2%

-36.3%

-26.1%

-35.8%

+596.0%

+591.0%

1W -$0.97

1M -$5.48

3M -$3.38

6M -$5.37

YTD +$8.23

1Y +$8.21

ANL was +591.0% over the past year, -35.8% over six months, +596.0% year to date, -9.2% in the last week.

12 Months vs Market

ANL

+591.0%

DIA

+10.3%

SPY

+11.0%

QQQ

+9.4%

IWM

+14.6%

Over the past 12 months ANL returned +591.0% versus DIA (Dow) +10.3%, SPY (S&P 500) +11.0%, QQQ (Nasdaq 100) +9.4% and IWM (Russell 2000) +14.6%.

Volume & Liquidity 0.65× 3-mo avg

Today 139,892 3-mo avg 215.4K

127.2K

332.7K

215.4K

198.5K

YTD

359.6K

401.7K

ANL most recently traded 139,892 shares against a 3-month average daily volume of 215.4K.

More News

September 30, 2026

Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC

September 08, 2026

Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress

August 14, 2026

Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia

August 03, 2026

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

July 16, 2026

Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists

July 13, 2026

What's going on in today's pre-market session ↗

April 16, 2026

Via Chartmill

Adlai Nortye Announces $150.0 Million Private Placement Equity Financing

April 16, 2026

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations

Wednesday's session: gap up and gap down stocks ↗

April 15, 2026

Via Chartmill

February 12, 2026

What's going on in today's session ↗

February 03, 2026

Via Chartmill

Adlai Nortye Announces $140.0 Million Private Placement Equity Financing

February 03, 2026

Top movers analysis in the middle of the day on 2026-01-30: top gainers and losers in today's session. ↗

Let's take a look at the stocks that are in motion in today's session. ↗

January 30, 2026

Via Chartmill

January 30, 2026

Via Chartmill

Which stocks are moving before the opening bell on Friday? ↗

January 30, 2026

Via Chartmill

What's going on in today's after hours session ↗

January 29, 2026

Via Chartmill

Top movers in Thursday's session ↗

January 29, 2026

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

December 30, 2025

Via Chartmill

Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China

December 29, 2025

Adlai Nortye to Participate in Upcoming Investor Conferences

November 21, 2025

Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 22, 2025

Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 13, 2025